BioSpace News Archive

Predictive Oncology Inc. announced that it has entered into definitive agreements with several institutional and accredited investors for the issuance and sale of an aggregate of approximately 4,222,288 shares of its common stock, at a purchase price of $1.75 per share, for gross proceeds of approximately $7.4 million in a registered direct offering priced at-the-market under Nasdaq rules.

Ascensia Diabetes Care, a leading global diabetes care company and the maker of the CONTOUR® range of blood glucose monitoring systems, has once again decided to support the Spare A Rose campaign, organized by Life for a Child, for the fourth consecutive year.

New enterprise, Rentschler ATMP Ltd., is part of continuous innovation at Rentschler Biopharma and supports ongoing strategic international expansion

While many university classes across Canada are being held online, some programs require in-person learning and access to on- and off-campus research and learning facilities.

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced an agreement whereby Tonix has licensed technology using oxytocin-based therapeutics for the treatment of Prader-Willi syndrome and non-organic failure to thrive disease from Inserm.

Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today reported financial results for its fiscal quarter ended December 31, 2020.

Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced financial results for the quarter ended December 31, 2020.

-- Revenues of $1.04 Billion in 2020, GAAP Loss per Share of $0.70 and Basic and Diluted Non-GAAP Earnings per Share of $0.43 -- -- Financial Expectations for 2021 Reflect Anticipated Growth of Proprietary Products and Investment in Strategic Priorities for Long-Term Value Creation --

PYC Therapeutics (ASX: PYC), a biotechnology company developing a new generation of precision RNA therapeutics to change the lives of patients with inherited diseases, today announced that Sahm Nasseri , incoming Chief Executive Officer of U.S. Operations, has been invited to participate in a virtual panel discussion and Q&A at the 2021 BIO CEO & Investor Digital Conference.

BrainCool AB (publ), a Swedish medical device innovator, and a world leader in medical cooling technology for therapeutic hypothermia (brain cooling) and oncology, announced today that the U.S. Food and Drug Administration (FDA) has granted “Breakthrough Device” Designation for the Cooral® System, for prevention of Oral Mucositis (OM).